|Dr. Jonathan C. Javitt M.D., M.P.H.||Co-Founder, Chairman & CEO||471.05k||N/A||1957|
|Mr. Robert Besthof M.I.M.||Head of Operations & Chief Commercial Officer and Patient Officer||214.38k||N/A||1966|
|Prof. Daniel C. Javitt||Co-Founder & Chairman of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. James H. Brandon CPA||Acting Chief Financial Officer||N/A||N/A||1956|
|Ms. Alessandra Daigneault Esq.||Chief Corp. Officer, Gen. Counsel, Sec. & Acting Treasurer||N/A||N/A||1964|
|Mr. Jack Hirschfield||Sr. Director of Corp. Communications & External Affairs||N/A||N/A||N/A|
|Dr. Philip T. Lavin||Chief Methodologist||N/A||N/A||1947|
|Dr. Dennis K. McBride Ph.D.||Chief Strategy Officer & Sr. Scientist||N/A||N/A||N/A|
|Mr. Randolph Guggenheimer III||Chief Bus. Officer||N/A||N/A||N/A|
NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NRx Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.